Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,884 INR | -0.55% | +2.90% | -6.13% |
Apr. 16 | Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak | CI |
Mar. 28 | Alkem Laboratories Forms Subsidiary for Medical Devices Business | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.07 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.39 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.13% | 7.04B | C- | ||
+25.83% | 661B | C+ | ||
+26.51% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+14.68% | 231B | B+ | ||
+5.03% | 200B | B- | ||
-9.00% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALKEM Stock
- Ratings Alkem Laboratories Limited